TNBC Clinical News (2 of 5)

Immunomedics’ sacituzumab govitecan drug shrinks tumors of metastatic Triple Negative Breast Cancer Patients

IMMU-132-01 Phase 1/2 clinical trial using Immunomedics’ sacituzumab govitecan drug has revealed that this drug increases survival time and shrinks tumor in metastatic triple negative breast patients.

In this clinical trial, 108 metastatic breast cancer patients who had been previously treated with other medications received the sacituzumab govitecan drug. The sacituzumab govitecan drug is unique in that it combines an antibody with a chemotheraphy drug to better target cancer cells. Specically, when the antibody portion binds to the Trop-2 antigen which is found on most breast cancer cells, the drug is released within those cells and into the areas of the tumor. Thus, sacituzumab govitecan drug provides targeted drug delivery to the cancer cells and reduces the tixic effect of the drug to healthy cell.

After approximately 10 months of treatment with the sacituzumab govitecan drug, tumor reduction was observed in 33% of patients, including three patients with a complete tumor clearance. The positive response to treatment with the sacituzumab govitecan drug lasted for about 8 months, with 6 patients having responses that lasted for more than 12 months. About 45% of patients experienced complete or partial response or stable disease for at least 6 months. The median progress free survival was 5.5 months and the median overall survival was 13 months.

Read more about Immunomedics’ study here.

Chemotherapy within 30 days of surgery improves survival rate among triple negative breast cancer patients

A review of data from nearly 700 patients with triple negative breast cancer has revealed that delays of more than 30 days in initiating chemotherapy after surgery were associated with lower disease-free survival, lower distant recurrence-free survival and lower overall survival. These results were presented at the Annual San Antonio Breast Cancer Symposium in December 2018.

 

In this data analysis study, the researchers reviewed data for 687 women with stage I, II or III triple negative breast cancer. The time to chemotherapy was less than 30 days in 189 patients, 31-60 days in 329 patients, 61-90 days in 115 patients and more than 91 days in 54 patients.

 

When comparing these 4 groups (eg., one group was the patients who had chemotherapy less than 30 days after surgery), the overall survival at 10 years for patients in the < 30 days of surgery group was 82%, 67.4% for those in the 31-60 days group, 67.1% for those in the 61-90 days group and 65.1% for those in the > 91 days group. Disease-free survival at 10 years was 81.4% for patients in the < 30 days, 68.8% for the 31-60 days group, 70.8% for those in the 61-90 days group and 68.1% for those in the > 91 days group. Distant recurrence-free survival at 10 years was 80.2% for patients in the < 30 days, 64.9% for the 31-60 days group, 67.5% for those in the 61-90 days group and 58.6% for those in the > 91 days group. Overall, patients receiving chemotherapy within 30 days after surgery had more than 10% higher 10-year survival rates compared to patients receiving chemotherapy more 30 days after surgery.

 

Read more about this study here.